Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Future Oncol
; 5(4): 421-32, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-19450171
ABSTRACT
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis. It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-molecule inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets. This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinazolinas
/
Inibidores da Angiogênese
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Reino Unido